Antibody therapies augment the naturally occurring antibodies in our immune system that help the immune system recognize infections.3 Antibodies have been developed to help identify and attack malignant cells in multiple myeloma, and in other cancers. Multiple novel combinations of antibody therapeutics are now available for the management of multiple myeloma. These include1,4-6:
In addition to these therapies, multiple other therapies are now in development called bispecific antibodies. These antibodies can help bring together T cells, which are immune cells involved in targeting and destroying cancer cells, and specific receptors on cancer cells. In this way, bispecific antibodies can help the immune system recognize and destroy cancer. One target on cancer cells in multiple myeloma is known as B-cell maturation antigen (BCMA). With approval secured for one bispecific antibody, teclistamab, additional bispecific antibodies targeting BCMA are in active development for multiple myeloma, including7,8:
If you have already received multiple earlier lines of therapy, discussing these therapies with your physician might give rise to consideration of clinical trial opportunities in developing lines of therapy.8
One key target on cancer cells in multiple myeloma is BCMA, which is generally expressed to a greater degree on abnormal plasma cells than normal plasma cells.4 Several bispecific antibodies targeting BCMA have been approved for the treatment of multiple myeloma, including elranatamab and teclistamab. Other bispecific antibodies targeting BCMA are in active development for multiple myeloma, including:5-10
While multiple antibody therapies have been incorporated in the National Comprehensive Cancer Institute (NCCN) guidelines for the treatment of multiple myeloma, these guidelines also support enrollment in clinical trials of new therapies. Discussing therapies in development for multiple myeloma with your physician might give rise to consideration of clinical trial opportunities in developing lines of therapy.11
